7
10
CHEMISTRY & BIODIVERSITY – Vol. 10 (2013)
1
13
ꢁ
ꢁ
1
9
040, 890. H- and C-NMR: Tables 1 and 2. ESI-MS (neg.): 1281 ([MꢁH] ), 1119 ([MꢁGlcꢁH] ),
ꢁ
ꢁ
ꢁ
ꢁ
57 ([Mꢁ2GlcꢁH] ), 795 ([Mꢁ3GlcꢁH] ), 633 ([Mꢁ4GlcꢁH] ), 471 ([Mꢁ5GlcꢁH] ). HR-
þ
þ
25
FAB-MS (pos.): 1305.6090 ([MþNa] , C H NaO ; calc. 1305.6091).
54
88
Cytotoxicity Assays. Test compounds were dissolved in DMSO, diluted to 2 mg/ml in RPMI 1640
medium with free fetal bovine serum (FBS), and stored at ꢁ208. The human tumor cell lines used in the
present study were supplied from the Tumor Hospital of Harbin Medical University. They were
maintained as adherent-type cultures under standard conditions. HepG-2, Skov3, and A549 cells were
cultured at 378 under a humidified atmosphere of 5% CO in RPMI 1640 medium supplemented with
2
1
0% FBS and subculture twice weekly to maintain continuous logarithmic growth. Cells were seeded into
3
(
aliquots/well) at a density of 8ꢂ10 cells/ml for 24 h. Serial drug dilutions were prepared in medium
immediately prior to each assay. Thereafter, aliquots of serial dilution of each test compound were added
parallel triplicate wells were set), and then the cells were incubated for 48 h in 5% CO incubator at 378.
(
2
The cell viability was assessed through a MTT conversion assay. Aliquots of MTT soln. (5 mg/ml in PBS)
were added to every well. Then, the plates were incubated for 4 h at 378. The medium was then
completely removed from the wells and replaced with 100 ml of DMSO. The OD of the dissolved
formazan dye was recorded at 540 nm using a microplate spectrophotometer (BMG Labtechnologies,
Fluostar Optima). The data were expressed as meanꢀstandard deviation. The standard Microsoft Excel
program was used for the calculation of the IC values.
50
REFERENCES
[
1] L. M. Perry, ꢃMedicinal Plants of East and Southeast Asia Attributed Properties and Uses,ꢂ 1980,
229.
[
[
2] O. K. Kim, E. B. Lee, S. S. Kang, Korean J. Pharmacogn. 1992, 24, 219.
3] S. Saito, J. Ebashi, S. Sumita, T. Furumoto, Y. Nagamura, K. Nishida, I. Ishiguro, Chem. Pharm. Bull.
1993, 41, 1395.
[
[
[
[
[
[
4] M. Yoshikawa, E. Harada, H. Matsuda, T. Murakami, J. Yamahara, N. Murakami, Chem. Pharm.
Bull. 1993, 41, 2069.
5] M. Yoshikawa, T. Murakami, E. Harada, N. Murakami, J. Yamahara, H. Matsuda, Chem. Pharm.
Bull. 1996, 44, 1915.
6] M. Yoshikawa, H. Matsuda, E. Harada, T. Murakami, N. Wariishi, J. Yamahara, N. Murakami,
Chem. Pharm. Bull. 1994, 42, 1354.
7] M. Yoshikawa, T. Murakami, E. Harada, N. Murakami, J. Yamahara, H. Matsuda, Chem. Pharm.
Bull. 1996, 44, 1923.
8] M. Yoshikawa, S. Yoshizumi, T. Ueno, H. Matsuda, T. Murakami, J. Yamahara, N. Murakami, Chem.
Pharm. Bull. 1995, 43, 1878.
9] L. Yin, X. Bian, H. Xiao, H. Kuang, Acta Chin. Med. Pharmacol. 2010, 38, 18.
[
[
[
[
[
[
[
[
10] L. Wang, H. Xiao, X. Zhang, M. Wang, L. Li, Acta Chin. Med. Pharmacol. 2010, 38, 30.
11] H. Kuang, H. Sun, N. Zhang, Y. Okada, T. Okuyama, Chem. Pharm. Bull. 1996, 44, 2183.
12] Z. Q. Ma, S. J. Song, W. Li, S. X. Xu, J. Asian Nat. Prod. Res. 2005, 7, 817.
13] S. Song, N. Nakamura, C. Ma, M. Hattori, S. Xu, Phytochemistry 2001, 56, 491.
14] C. Yang, Q. An, Z. Xiong, Y. Song, K. Yu, F. Li, Planta Med. 2009, 75, 656.
15] T. Mosmann, J. Immunol. Methods 1983, 65, 55.
16] S. S. M. Konstantinov, H. Eibl, M. R. Berger, Br. J. Haematol. 1999, 107, 365.
17] B. Liu, Y. Yi, L. Li, P. Sun, W. Yuan, G. Sun, H. Han, M. Xue. Chem. Biodiversity 2008, 5, 1288.
Received March 17, 2012